The Global Eosinophilic Esophagitis Market, by Drug Class (Corticosteroids: Budesonide {Jorveza and Off-label budesonide} and Fluticasone; Proton Pump Inhibitor (PPI): Omeprazole, Esomeprazole, and Others; and Late Stage Pipeline Drugs: Dupixent, APT-1011, Lirentelimab (AK002), Cendakimab, Etrasimod, TAK-721, and Omilancor (BT-11)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 138.4 Mn in 2021 and is expected to exhibit a CAGR of 33.3% during the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.
Request Sample Report (Including Full TOC, Table & Figures) @
https://www.coherentmarketinsights.com/insight/request-sample/4909
Key players are adopting inorganic growth strategies such as acquisition and collaboration is expected to drive the global eosinophilic esophagitis market growth over the forecast period. For instance, in May 2019, EsoCap AG is developing a novel smart drug delivery technology collaborated with LTS Lohmann Therapy-Systeme AG a company offers the innovative drug delivery system to cooperate on the industrial development of a drug delivery technology for diseases of the upper gastrointestinal tract.
Moreover, growing approvals for newer products is expected to drive the market growth. For instance, on October 8, 2021, Tezepelumab was granted Orphan Drug Designation (ODD) in the U.S. by the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE). Tezepelumab is a human monoclonal antibody developed by AstraZeneca in collaboration with Amgen
The coronavirus (COVID-19) pandemic was first reported on December 31, 2019 in Wuhan, China. The World Health Organization (WHO) declared the COVID-19 a pandemic on March 11, 2020. The pandemic caused disruptions in conducting clinical trials. This led to delay in product approvals and thereby hindered the market growth. The COVID-19 pandemic has also affected the economy by directly affecting the production and demand, creating disruptions in distribution channels, and causing a negative financial impact on companies and financial markets.
Request PDF Brochure with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-pdf/4909
Growing funding and investments to initiate clinical trials associated with eosinophilic esophagitis (EoE) is expected to drive the market growth. For instance, in November 2021, the Children’s Hospital of Philadelphia (CHOP) received funding of US$ 2 million from the Mondre and Lane families to launch a new clinical trial at the CHOP for patients suffering from severe food allergies such as eosinophilic esophagitis (EoE).
The global eosinophilic esophagitis market is expected to exhibit a CAGR of 33.3% during the forecast period. Increasing focus of key players on launching new products in the market is projected to drive the global eosinophilic esophagitis market growth over the forecast period. For instance, England and Wales’ National Institute for Health and Care Excellence (NICE), an executive non-departmental public body of the Department of Health in England, approved Jorveza budesonide orodispersible tablet for the treatment of eosinophilic esophagitis in adults on June 23, 2021
Based on drug class, the proton pump inhibitor (PPI) segment is expected to exhibit the highest CAGR in the global eosinophilic esophagitis market over the forecast period. Market players are focused on producing PPI for the treatment of EoE which is expected to augment the market growth over the forecast period. For instance, Glenmark Pharmaceuticals a pharmaceutical company engaged in manufacturing Omeprazole, a PPI for the treatment of reflux-mediated esophageal eosinophilia.
Among distribution channels, the hospital pharmacies segment is projected to register the highest CAGR over the forecast period in the global esophageal eosinophilia market, as the majority of eosinophilic esophagitis (EoE) drugs is sold by hospital pharmacies
Among regions, Asia Pacific is anticipated to expand at the highest CAGR in the global eosinophilic esophagitis (EoE) market over the forecast period. Strong focus of key players on growth strategies such as collaboration, acquisition, etc. in the Asia Pacific region is expected to drive the market growth. For instance, in May 2021, Landos Biopharma, Inc. a late clinical-stage biopharmaceutical company entered into an exclusive collaboration and license agreement with LianBio, a biotechnology company dedicated to bringing the medicines for patients in China and other major Asian markets, for the development and commercialization of omilancor and NX-13 in Greater China (mainland China, Hong Kong, Taiwan, and Macau) and other selected Asian countries.
Major players operating in the global eosinophilic esophagitis (EoE) market include Ellodi Pharmaceuticals, EsoCap AG, GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Cipla Limited, Sun Pharmaceutical Industries Limited, AstraZeneca Plc, Sanofi S.A., Arena Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Revolo Biotherapeutics, Allakos Inc., Bristol-Myers Squibb Co, Calypso Biotech, DBV Technologies, Landos Biopharma, Inc., Glenmark Pharmaceuticals, Alkem Laboratories Ltd., Quorum Innovations LLC, and Dr. Falk Pharma GmbH
Reasons to buy this Eosinophilic Esophagitis Market Report
☑ It attempts an analysis of the competing scenario.
☑ The current and exceptional product revenue market.
☑ An in-depth data on the regional investigation and competitive landscape structure.
☑ It benefits in creating an awareness of the important key product segments.
☑ The marketing strategies, opportunities, and development factors are explained.
☑ Eosinophilic Esophagitis market size estimation and recent advancements in the industry are explained.
SPECIAL OFFER (Avail an Up-to 30% discount on this report ) @
https://www.coherentmarketinsights.com/insight/buy-now/4909
Table of Content
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Pipeline Analysis
- Regulatory Scenario
- Recent Product Approval/Launch
- PEST Analysis
- Epidemiology
- Global Eosinophilic Esophagitis Market – Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply and Demand Analysis
- Key Developments
- Global Eosinophilic Esophagitis Market , By Drug Class, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 – 2028
- Segment Trends
- Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Budesonide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Jorveza
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Off-label budesonide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Jorveza
- Fluticasone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Budesonide
- Proton Pump Inhibitor (PPI)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Omeprazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Esomeprazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Omeprazole
- Late Stage Pipeline Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Dupixent
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- APT-1011
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Lirentelimab (AK002)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Cendakimab
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Etrasimod
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- TAK-721
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Omilancor (BT-11)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Dupixent
- Introduction
- Global Eosinophilic Esophagitis Market, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 – 2028
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Introduction
- Global Eosinophilic Esophagitis Market, By Region, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, For Regions, 2017–2028
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2028, (US$ Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2028, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2028, (US$ Mn)
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2028, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2028, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 – 2028, (US$ Mn)
- North Africa
- Central Africa
- South Africa
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Ellodi Pharmaceuticals.
- Company Highlights
- Product Portfolio
- Key Highlights
- Strategies
- EsoCap AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Strategies
- GlaxoSmithKline plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Cipla Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- AstraZeneca Plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Arena Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Strategies
- Revolo Biotherapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Strategies
- Allakos Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Strategies
- Bristol-Myers Squibb Co
- Company Highlights
- Product Portfolio
- Key Highlights
- Strategies
- Calypso Biotech
- Company Highlights
- Product Portfolio
- Key Highlights
- Strategies
- DBV Technologies
- Company Highlights
- Product Portfolio
- Key Highlights
- Strategies
- Landos Biopharma, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Strategies
- Glenmark Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Alkem Laboratories Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Quorum Innovations LLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Strategies
- Falk Pharma GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Strategies
- Ellodi Pharmaceuticals.
- Analyst Views
- Section
- Research Methodology
- About us
About Coherent Market Insights
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837